Status:
UNKNOWN
Survivin as Predictive Biomarker for RA
Lead Sponsor:
Vastra Gotaland Region
Conditions:
Rheumatoid Arthritis
Arthralgia
Eligibility:
All Genders
Brief Summary
Purpose: to examine the possibility of using the onco-protein survivin as a predictive biomarker for identifying individuals at risk of developing rheumatoid arthritis within a cohort of patients seek...
Detailed Description
The study will analyse survivin levels in a non-selected material within a cohort of patients seeking help at their primary health care for joint pain, stiffness, swelling etc. Patients presenting wit...
Eligibility Criteria
Inclusion
- Patients seeking treatment at the primary health care for problems with their joints (pain, stiffness).
Exclusion
- Patients diagnosed with RA
Key Trial Info
Start Date :
June 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
6000 Patients enrolled
Trial Details
Trial ID
NCT03444623
Start Date
June 1 2013
End Date
December 1 2023
Last Update
May 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept of Rheumatology and Inflammation research
Gothenburg, Sweden